OncoMatch/Clinical Trials/NCT04920149
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Is NCT04920149 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Mesalamine for lynch syndrome.
Treatment: Mesalamine — Multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with 2000mg mesalamine, or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients during and following daily intake for 2 years.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MLH1 pathogenic mutation
carriers of a germline pathologic mutation in one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
Required: MSH2 pathogenic mutation
carriers of a germline pathologic mutation in one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
Required: EPCAM pathogenic mutation
carriers of a germline pathologic mutation in one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
Required: MSH6 pathogenic mutation
carriers of a germline pathologic mutation in one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
Excluded: PMS2 pathogenic mutation
Carriers of germline mutations in PMS2
Disease stage
Excluded: Stage III, IV
Demographics
Lab requirements
Kidney function
Renal insufficiency (GFR <30ml/min/1.73m2)
Liver function
Severe liver disease or liver failure (elevation of liver enzymes above 3xULN)
Renal insufficiency (GFR <30ml/min/1.73m2); Severe liver disease or liver failure (elevation of liver enzymes above 3xULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04920149 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require MLH1?
Yes, MLH1 pathogenic mutation is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 pathogenic mutation is a required biomarker for enrollment.
Does this trial require EPCAM?
Yes, EPCAM pathogenic mutation is a required biomarker for enrollment.
Are patients with PMS2 alterations eligible?
No. PMS2 pathogenic mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify